Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating biomarkers of bevacizumab activity in patients with breast cancer.

Cancer biology & therapy - 1 Jan 2008

Denduluri Neelima, Yang Sherry X, Berman Arlene W, Nguyen Diana, Liewehr David J, Steinberg Seth M, Swain Sandra M

Abstract excerpt

PURPOSE: Noninvasive markers of anti-vascular endothelial growth factor (VEGF) therapy are needed. Soluble vascular cell adhesion molecule (sVCAM-1), soluble VEGF receptor-2 (sVEGFR-2), and plasma VEGF levels were assessed as potential biomarkers of therapy with bevacizumab. Tumor samples were ev...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Enzyme-Linked Immunosorbent Assay

Share to Vascular Cell Adhesion Molecule-1

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 18059178
DOI: 10.4161/cbt.7.1.5337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18059178-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Circulating biomarkers of bevacizumab activity in patients with breast cancer.PMID 18059178Read ↗

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.Semantic proximity Read ↗

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).Semantic proximity Read ↗

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.Semantic proximity Read ↗

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.Semantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.Semantic proximity Read ↗

Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.